Overview

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Collaborator:

GlaxoSmithKline

Treatments:

Bupropion
Nicotine
Varenicline